Παρασκευή 12 Οκτωβρίου 2018

Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies

Publication date: Available online 12 October 2018Source: Autoimmunity ReviewsAuthor(s): Gwendoline Montes Diaz, Raymond Hupperts, Judith Fraussen, Veerle SomersAbstractMultiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) in which demyelination and neurodegeneration occurs. The immune system of MS patients is characterized by a dysregulation in the balance between pro- and anti-inflammatory immune cells, whereby both the innate and adaptive immune system are involved. Dimethyl fumarate (DMF) was licensed in 2013 as an oral first-line therapy for relapsing-remitting (RR)MS patients. It has a strong efficacy with neuroprotective and immunomodulatory effects and a favourable benefit-risk profile. However, the effects of DMF on the immune sys...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2OTGCGs

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.